Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.

Gris-Oliver, Albert; Palafox, Marta; Monserrat, Laia; Brasó-Maristany, Fara; Òdena, Andreu; Sánchez-Guixé, Mònica; Ibrahim, Yasir H; Villacampa, Guillermo; Grueso, Judit; Parés, Mireia; Guzmán, Marta; Rodríguez, Olga; Bruna, Alejandra; Hirst, Caroline S; Barnicle, Alan; de Bruin, Elza C; Reddy, Avinash; Schiavon, Gaia; Arribas, Joaquín; Mills, Gordon B; Caldas, Carlos; Dienstmann, Rodrigo; Prat, Aleix; Nuciforo, Paolo; Razavi, Pedram; Scaltriti, Maurizio; Turner, Nicholas C; Saura, Cristina; Davies, Barry R; Oliveira, Mafalda; Serra, Violeta

Gris-Oliver, Albert; Palafox, Marta; Monserrat, Laia; Brasó-Maristany, Fara; Òdena, Andreu; Sánchez-Guixé, Mònica; Ibrahim, Yasir H; Villacampa, Guillermo; Grueso, Judit; Parés, Mireia; Guzmán, Marta; Rodríguez, Olga; Bruna, Alejandra; Hirst, Caroline S; Barnicle, Alan; de Bruin, Elza C; Reddy, Avinash; Schiavon, Gaia; Arribas, Joaquín; Mills, Gordon B; Caldas, Carlos; Dienstmann, Rodrigo; Prat, Aleix; Nuciforo, Paolo; Razavi, Pedram; Scaltriti, Maurizio; Turner, Nicholas C; Saura, Cristina; Davies, Barry R; Oliveira, Mafalda; Serra, Violeta.

Afiliação

Gris-Oliver A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Palafox M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Monserrat L; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Brasó-Maristany F; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer, Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Òdena A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Ibrahim YH; Weil Cornell Medicine, New York, New York.
Villacampa G; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Grueso J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Parés M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Bruna A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge.
Hirst CS; Early Oncology, AstraZeneca, Cambridge, United Kingdom.
Barnicle A; Early Oncology, AstraZeneca, Cambridge, United Kingdom.
de Bruin EC; Early Oncology, AstraZeneca, Cambridge, United Kingdom.
Reddy A; Early Oncology, AstraZeneca, Cambridge, United Kingdom.
Schiavon G; Early Oncology, AstraZeneca, Cambridge, United Kingdom.
Arribas J; Growth Factors Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Mills GB; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Caldas C; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
Dienstmann R; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
Prat A; Department of Cell Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, Oregon.
Nuciforo P; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Razavi P; Department of Oncology and Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom.
Scaltriti M; Cambridge Breast Unit, NIHR Cambridge Biomedical Research Centre and Cambridge Experimental Cancer Medicine Centre at Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Turner NC; Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Saura C; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer, Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Davies BR; Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.
Oliveira M; SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.
Serra V; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.

Clin Cancer Res ; 26(14): 3720-3731, 2020 07 15.

Article em En | MEDLINE | ID: mdl-32220884

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia; Biomarcadores Tumorais/genética; Neoplasias da Mama/terapia; Resistencia a Medicamentos Antineoplásicos/genética; Inibidores de Proteínas Quinases/farmacologia; Animais; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Mama/patologia; Mama/cirurgia; Neoplasias da Mama/genética; Neoplasias da Mama/patologia; Quimioterapia Adjuvante/métodos; Classe I de Fosfatidilinositol 3-Quinases/genética; Análise Mutacional de DNA; Feminino; Humanos; Mastectomia; Camundongos; Mutação; Paclitaxel/farmacologia; Paclitaxel/uso terapêutico; Prognóstico; Inibidores de Proteínas Quinases/uso terapêutico; Proteínas Proto-Oncogênicas c-akt/genética; Pirimidinas/farmacologia; Pirimidinas/uso terapêutico; Pirróis/farmacologia; Pirróis/uso terapêutico; Proteínas Quinases S6 Ribossômicas 70-kDa/metabolismo; Transdução de Sinais/efeitos dos fármacos; Serina-Treonina Quinases TOR/genética; Proteína 1 do Complexo Esclerose Tuberosa/genética; Ensaios Antitumorais Modelo de Xenoenxerto

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google